Literature DB >> 8794986

Urinary excretion profile of torasemide and its diuretic action in dogs.

Y Sogame1, K Okano, K Hayashi, T Uchida, Y Tsuda.   

Abstract

The plasma concentration profile, urinary excretion rate and diuretic response were studied in anaesthetized dogs after an intravenous administration of torasemide or furosemide. The urinary excretion rate of furosemide decreased rapidly after administration. The plasma concentration, which is related to the urinary excretion profile, also decreased rapidly. The diuretic response, which reflected the excretion rate, occurred rapidly after administration but lasted for a short time. The urinary excretion rate of torasemide was much lower than that of furosemide and decreased slowly after administration. The plasma concentration also decreased slowly. The diuretic response to torasemide occurred more slowly but lasted longer than the response to furosemide. These results suggest that the diuretic response profile of either diuretic depends on their urinary excretion rate, and that the difference in the diuretic response between torasemide and furosemide may be explained by the different transfer rate of the drugs from the plasma to the nephron.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794986     DOI: 10.1111/j.2042-7158.1996.tb05936.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Safety of torasemide in healthy adult dogs administered daily for 26 weeks.

Authors:  Evelyne Coussanes; Emilie Guillot; Reynald Magnier; Anne Geneteau; Jonathan Elliott
Journal:  J Vet Pharmacol Ther       Date:  2021-11-17       Impact factor: 1.567

2.  Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study.

Authors:  V Chetboul; J-L Pouchelon; J Menard; J Blanc; L Desquilbet; A Petit; S Rougier; L Lucats; F Woehrle
Journal:  J Vet Intern Med       Date:  2017-10-04       Impact factor: 3.333

3.  Long-term Stability of a Compounded Suspension of Torsemide (5 mg/mL) for Oral Administration.

Authors:  D Adin; P R Johnson; C H Kim; T Nguyenba; S Rosen
Journal:  J Vet Intern Med       Date:  2017-09-15       Impact factor: 3.333

4.  Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.

Authors:  Darcy Adin; Kari Kurtz; Clarke Atkins; Mark G Papich; Shelly Vaden
Journal:  J Vet Intern Med       Date:  2019-11-26       Impact factor: 3.333

5.  Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats.

Authors:  Marine Roche-Catholy; Dominique Paepe; Mathias Devreese; Bart J G Broeckx; Frederique Woehrlé; Marc Schneider; Andrea Garcia de Salazar Alcala; Arnaut Hellemans; Pascale Smets
Journal:  J Vet Intern Med       Date:  2022-07-30       Impact factor: 3.175

6.  Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study.

Authors:  Beatrice Besche; Thomas Blondel; Emilie Guillot; Catherine Garelli-Paar; Mark A Oyama
Journal:  J Vet Intern Med       Date:  2020-08-07       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.